http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101009594-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-422 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-422 |
| filingDate | 2008-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2011-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2011-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101009594-B1 |
| titleOfInvention | FFA inhibitor having cyclic amidine at P4 position, derivative thereof, preparation method and pharmaceutical composition containing same |
| abstract | The present invention provides an oxazolidinone derivative having a novel cyclic amidine group represented by Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, and a pharmaceutically acceptable salt thereof, a method for preparing the same The invention relates to a pharmaceutical composition containing.n n n [Formula 1]n n n n n n n n [In Formula 1, A is selected from the following structures.]n n n n n n n n Oxazolidinone derivatives having cyclic amidine groups, prodrugs thereof, hydrates thereof, solvates thereof, isomers thereof and pharmaceutically acceptable salts thereof according to the present invention are thromboembolism with anticoagulants through inhibition of coagulation factor VIIa. And it can be usefully used for the treatment of tumors.n n n n Cyclic amidine, oxazolidinone, factor Xa, anticoagulant |
| priorityDate | 2007-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 250.